Polyrizon Ltd. Initiates Preclinical Studies for Innovative Intranasal Benzodiazepine Treatment Targeting $3.15 Billion Epilepsy Market

Reuters

05/13

<a href="https://laohu8.com/S/PLRZ">Polyrizon Ltd.</a> Initiates Preclinical Studies for Innovative Intranasal Benzodiazepine Treatment Targeting $3.15 Billion Epilepsy Market

Polyrizon Ltd. (Nasdaq: PLRZ), a development stage biotech company specializing in innovative intranasal hydrogels, has announced the initiation of preclinical studies for intranasal Benzodiazepines (BZDs). The studies aim to address the $3.15 billion epilepsy market, focusing on acute repetitive seizures and status epilepticus. Utilizing Polyrizon's proprietary drug delivery platform, the intranasal administration of BZDs is designed to offer rapid, targeted, and patient-friendly seizure rescue therapy. Conducted in collaboration with Professor Fabio Sonvico of the University of Parma, the studies leverage Polyrizon's Trap and Target™ (T&T) platform to enhance the emergency treatment of seizures, providing a faster and more accessible solution for managing acute seizures outside of clinical settings. This initiative marks a significant milestone in improving treatment options for epilepsy patients worldwide.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9450305-en) on May 13, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2535596722"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535596722\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535596722?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-13 19:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535596722","market":"us","top_or_hot":-1,"title":"Polyrizon Ltd. Initiates Preclinical Studies for Innovative Intranasal Benzodiazepine Treatment Targeting $3.15 Billion Epilepsy Market","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PLRZ\">Polyrizon Ltd.</a> Initiates Preclinical Studies for Innovative Intranasal Benzodiazepine Treatment Targeting $3.15 Billion Epilepsy Market\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Polyrizon Ltd. (Nasdaq: PLRZ), a development stage biotech company specializing in innovative intranasal hydrogels, has announced the initiation of preclinical studies for intranasal Benzodiazepines (BZDs). The studies aim to address the $3.15 billion epilepsy market, focusing on acute repetitive seizures and status epilepticus. Utilizing Polyrizon's proprietary drug delivery platform, the intranasal administration of BZDs is designed to offer rapid, targeted, and patient-friendly seizure rescue therapy. Conducted in collaboration with Professor Fabio Sonvico of the University of Parma, the studies leverage Polyrizon's Trap and Target™ (T&amp;T) platform to enhance the emergency treatment of seizures, providing a faster and more accessible solution for managing acute seizures outside of clinical settings. This initiative marks a significant milestone in improving treatment options for epilepsy patients worldwide.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9450305-en) on May 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Polyrizon Ltd. Initiates Preclinical Studies for Innovative Intranasal Benzodiazepine Treatment Targeting $3.15 Billion Epilepsy Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPolyrizon Ltd. Initiates Preclinical Studies for Innovative Intranasal Benzodiazepine Treatment Targeting $3.15 Billion Epilepsy Market\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-13 19:45</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PLRZ\">Polyrizon Ltd.</a> Initiates Preclinical Studies for Innovative Intranasal Benzodiazepine Treatment Targeting $3.15 Billion Epilepsy Market\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Polyrizon Ltd. (Nasdaq: PLRZ), a development stage biotech company specializing in innovative intranasal hydrogels, has announced the initiation of preclinical studies for intranasal Benzodiazepines (BZDs). The studies aim to address the $3.15 billion epilepsy market, focusing on acute repetitive seizures and status epilepticus. Utilizing Polyrizon's proprietary drug delivery platform, the intranasal administration of BZDs is designed to offer rapid, targeted, and patient-friendly seizure rescue therapy. Conducted in collaboration with Professor Fabio Sonvico of the University of Parma, the studies leverage Polyrizon's Trap and Target™ (T&amp;T) platform to enhance the emergency treatment of seizures, providing a faster and more accessible solution for managing acute seizures outside of clinical settings. This initiative marks a significant milestone in improving treatment options for epilepsy patients worldwide.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9450305-en) on May 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"納斯達克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nNDL3kJGjQ:1","article_id":"2535596722","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535596722","pubTimestamp":1747136712,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Polyrizon Ltd. Initiates Preclinical Studies for Innovative Intranasal Benzodiazepine Treatment Targeting $3.15 Billion Epilepsy Market. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire  on May 13, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","PLRZ":"Polyrizon Ltd."},"translate_title":"Polyrizon Ltd.启动针对31.5亿美元癫痫市场的创新鼻内苯二氮卓类药物治疗的临床前研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLRZ":0.9,"NDAQ":0.9},"content_text":"Polyrizon Ltd. Initiates Preclinical Studies for Innovative Intranasal Benzodiazepine Treatment Targeting $3.15 Billion Epilepsy Market\n    \n\n        Polyrizon Ltd. (Nasdaq: PLRZ), a development stage biotech company specializing in innovative intranasal hydrogels, has announced the initiation of preclinical studies for intranasal Benzodiazepines (BZDs). The studies aim to address the $3.15 billion epilepsy market, focusing on acute repetitive seizures and status epilepticus. Utilizing Polyrizon's proprietary drug delivery platform, the intranasal administration of BZDs is designed to offer rapid, targeted, and patient-friendly seizure rescue therapy. Conducted in collaboration with Professor Fabio Sonvico of the University of Parma, the studies leverage Polyrizon's Trap and Target™ (T&T) platform to enhance the emergency treatment of seizures, providing a faster and more accessible solution for managing acute seizures outside of clinical settings. This initiative marks a significant milestone in improving treatment options for epilepsy patients worldwide.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9450305-en) on May 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}